Xin Lang Cai Jing·2025-10-22 05:50Group 1 - The core point of the news is that Dize Pharmaceutical experienced a decline of 5.09% in its stock price, reaching 60.82 yuan per share, with a trading volume of 286 million yuan and a turnover rate of 1.01%, resulting in a total market capitalization of 27.941 billion yuan [1] - Dize Pharmaceutical, established on October 27, 2017, and listed on December 10, 2021, is based in Wuxi, Jiangsu Province, and focuses on the research and industrialization of innovative drugs, with 100% of its main business revenue coming from drug sales [1] Group 2 - From the perspective of major fund holdings, Dize Pharmaceutical is heavily weighted in one fund managed by Guotai Asset Management, specifically the Guotai Junan Innovation Medicine Mixed Fund A (014157), which reduced its holdings by 47,000 shares in the second quarter, now holding 127,800 shares, accounting for 5.07% of the fund's net value [2] - The Guotai Junan Innovation Medicine Mixed Fund A has a current scale of 107 million yuan, with a year-to-date return of 20.54%, ranking 4208 out of 8160 in its category, and a one-year return of 16.73%, ranking 4501 out of 8026 [2]